The Vasculitis Foundation has announced the launch of a new support group for young adults with vasculitis, a group of autoimmune conditions that includes ANCA-associated vasculitis (AAV). The group will promote connections among young adults, from 18 to 30 years of age, living with vasculitis, which is marked by…
News
People with ANCA-associated vasculitis (AAV) have a higher risk of cardiovascular diseases and related mortality than people without the disease, according to a systematic review and meta-analysis of published studies. For example, the risk of venous thromboembolism, a blood clot that develops in a vein, was three times higher…
A Phase 1 clinical trial evaluating the safety and preliminary efficacy of Adicet Bio’s CAR T-cell therapy ADI-001 in people with autoimmune diseases, including ANCA-associated vasculitis (AAV), has started recruiting certain participants — and it’s expected to enroll AAV patients by the end of the year — the…
Patterns of lung damage on CT scans may help predict disease outcomes in people with ANCA-associated vasculitis (AAV) and determine which patients should receive more intensive treatment, a study in Germany suggests. Particularly, ground glass opacities (GGO), which are white diffuse regions due to fluid, airway collapse, tissue scarring,…
A European Medicines Agency (EMA) committee has issued a positive opinion recommending the approval of Fasenra (benralizumab) as an add-on treatment for adults with hard-to-treat eosinophilic granulomatosis with polyangiitis (EGPA). If approved for the recommended indication, the AstraZeneca therapy would be a new option for patients in…
High blood levels of the syndecan-1 protein, known to promote the survival of antibody-producing B cells, may help identify ANCA-associated vasculitis (AAV) patients with high disease activity — and those at risk of a poor prognosis — a new study suggests. The researchers defined two cut-off values of syndecan-1…
The U.S. Food and Drug Administration (FDA) has approved Fasenra (benralizumab) for treating adults with eosinophilic granulomatosis with polyangiitis (EGPA), a rare form of ANCA-associated vasculitis (AAV). Developed by AstraZeneca, Fasenra was already approved in more than 80 countries, including the U.S., as an add-on treatment…
Rituximab may be associated with a higher risk of serious adverse events, particularly infections, in people with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). Time to first serious adverse event, as well as to second and multiple serious adverse events, is significantly shorter for patients treated with rituximab…
Tavneos (avacopan) effectively induces disease remission in adults with ANCA-associated vasculitis (AAV) and diffuse alveolar hemorrhage (DAH), that is, bleeding from the small blood vessels in the lungs, according to a real-world study in the U.S. The therapy also let all patients reduce their dose of glucocorticoids, a…
ANCA-associated vasculitis (AAV) patients treated with rituximab are up to four times more likely to develop hypogammaglobulinemia (HGG), or low blood levels of antibodies that help fight off infections, than people with other autoimmune conditions. That’s according to a real-world study in China that also found that higher…
Recent Posts
- Let’s do away with pity parties and start practicing self-compassion
- Urine protein fragments may help assess kidney inflammation in AAV
- Most AAV patients in North America affected by lung complications
- Sharing what’s on your mind can ease loneliness in life with vasculitis
- Antibody type may influence cardiovascular risk timing in AAV